Healthcare Biz Roundup: UnitedHealth in the Cloud, Gilead Sciences FDA Review

UnitedHealth (NYSE:UNH) plans on launching a new cloud-computing platform geared for health care providers and insurers, according to the Wall Street Journal. Run by the firm’s health-services unit will charge for data storage and collect fees from developers for including their apps.

Investing Insights: MetLife Inc. Earnings: Powering Ahead.

Gilead Sciences (NASDAQ:GILD) anti-retroviral drug Truvada has been granted a priority-review schedule by the Food and Drug Administration, advancing what could become the first treatment labeled for HIV prevention.

Hospira (NYSE:HSP) shares power ahead after the specialty pharmaceutical company’s fourth quarter adjusted earnings per share from ongoing operations came in at $0.51 and revenues hit $1.01 billion, both topping expectations. CEO Michael Ball says a factory cited for manufacturing problems had reopened and was nearing previous production levels.

Express Scripts (NASDAQ:ESRX) and Medco Health (NYSE:MHS) shares climb after rumors of a report that the Federal Trade Commission is likely to approve their merger deal. The issue is likely to be decided by Federal Trade Commission Chairman Jon Leibowitz, who worked as Senator Herb Kohl’s leading antitrust advisor for years, market intelligence journal MLex says.

Earnings Report: Watson Pharmaceuticals Inc. Earnings: Revenue and Profit Climb.

To contact the reporter on this story: Tanya Harding at

To contact the editor responsible for this story: Damien Hoffman at